Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- GENERICS NEWS IN BRIEF
February 4, 2008
- Article 35 of the Amended Patent Law Should Be Properly Applied: Dr Akimoto
February 4, 2008
- How Can We Maximize the Value of Our Brand？
February 4, 2008
- R&D NEWS IN BRIEF
February 4, 2008
- Outline of FY2008 Revision of Medical Fees Approved by Chuikyo
February 4, 2008
- Cardiac Reagent NT-proBNP: RDKK
February 4, 2008
- Re-Pricing for Market Expansion Discourages Investment: PhRMA
February 4, 2008
- SELF-MEDICATION NEWS IN BRIEF
February 4, 2008
- 13 APIs Receive Approval Including Nexavar and Champix
February 4, 2008
- Risk of Death Decreases with Increases in Total Cholesterol Levels: Prof Hamazaki
February 4, 2008
- 42 New Technologies, 24 "Advanced Medical Technologies" Recommended for Insurance Coverage
February 4, 2008
- Precautions on "Impaired Performance" Necessary for Antihistaminics: sanofi-aventis
February 4, 2008
- REGULATORY NEWS IN BRIEF
February 4, 2008
- TOPICS／Debt of Failing Med. Institutions Triples in 2007
February 4, 2008
- Stelic Develops STNM-01 to Treat Stenosis in Crohn's Disease
February 4, 2008
- Nihon Chouzai to Discontinue Bulk Buying: President Mitsuhara
February 4, 2008
- MolMed to Start PIII Trial of HSV-TK Gene Therapy in Italy Using Takara Bio's RetroNectin
February 4, 2008
- Medical Pharmacy to Introduce Prices Based on "General Market Trends": Mr Kashiwagi
February 4, 2008
- Kyoto Univ. Creates iPS Cell Research Center
February 4, 2008
- CFS's Shareholders Reject Merger Proposal with Ain Pharmaciez
February 4, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…